Gilead Sciences Inc. won final approval Friday to pay $246.75 million to end allegations that anticompetitive conduct forced direct purchasers to pay more for drugs used to treat and prevent HIV.
Judge Edward M. Chen of the US District Court for the Northern District of California, granted the motion for final approval of the settlement, awarding the direct purchasers plaintiffs’ counsel $75 million in fees and $2.9 million in costs and litigation expenses along with a $40,000 class representative service award to KPH Healthcare Services Inc., also known as Kinney Drugs Inc.
The direct purchasers alleged the biopharmaceutical company used ...
